Association of circulating miR-20a, miR-27a, and miR-126 with non-alcoholic fatty liver disease in general population.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
11 12 2019
Historique:
received: 08 09 2019
accepted: 22 11 2019
entrez: 13 12 2019
pubmed: 13 12 2019
medline: 2 1 2021
Statut: epublish

Résumé

Non-alcoholic fatty liver disease (NAFLD) is closely associated with obesity, metabolic syndrome, and type II diabetes mellitus. Recently, circulating microRNAs (miRNAs) have been proposed as useful disease biomarkers. We examined whether circulating miRNAs, such as miR-20a, miR-27a, and miR-126, were useful biomarkers for NAFLD. We conducted a cross-sectional analysis of 527 subjects aged 39 years or older who had undergone a health examination in the Yakumo Study. Of the residents, 92 were diagnosed with NAFLD using a registered medical sonographer. Serum miR-20a, miR-27a and miR-126 levels were measured by quantitative real-time PCR. We then calculated the odds ratios for serum miRNA level changes according to the severity of NAFLD using normal liver status as the reference group. Serum levels of miR-20a and 27a, but not miR-126, were significantly lower in NAFLD subjects than normal subjects. Serum miR-20a and miR-27a levels were significantly lower in both male and female severe NAFLD subjects. Logistic regression analysis showed a significant relationship between low circulating miR-20a and 27a levels and severe NAFLD. Down-regulated circulating miR-20a and 27a levels were significantly associated with severe NAFLD in the general population. Circulating miR-20a and miR-27a may be useful biomarkers for severe NAFLD.

Identifiants

pubmed: 31827150
doi: 10.1038/s41598-019-55076-z
pii: 10.1038/s41598-019-55076-z
pmc: PMC6906495
doi:

Substances chimiques

Biomarkers 0
Circulating MicroRNA 0
MIRN126 microRNA, human 0
MIRN20a microRNA, human 0
MIRN27 microRNA, human 0
MicroRNAs 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

18856

Références

Metabolism. 2019 Mar;92:82-97
pubmed: 30502373
FEBS Lett. 2009 Feb 18;583(4):759-66
pubmed: 19185571
Clin Gastroenterol Hepatol. 2009 Oct;7(10):1104-12
pubmed: 19523535
Circ Res. 2017 Jan 20;120(2):381-399
pubmed: 28104771
Onco Targets Ther. 2016 May 27;9:3067-76
pubmed: 27313460
Nat Rev Clin Oncol. 2011 Jun 07;8(8):467-77
pubmed: 21647195
J Hepatol. 2015 Apr;62(1 Suppl):S47-64
pubmed: 25920090
J Clin Endocrinol Metab. 2012 Dec;97(12):E2271-6
pubmed: 23032062
Mech Ageing Dev. 2012 Nov-Dec;133(11-12):675-85
pubmed: 23041385
FEBS J. 2009 Apr;276(8):2348-58
pubmed: 19348006
Clin Chim Acta. 2015 Jun 15;446:267-71
pubmed: 25958847
AJR Am J Roentgenol. 2007 Dec;189(6):W320-3
pubmed: 18029843
Cell. 2004 Jan 23;116(2):281-97
pubmed: 14744438
Int J Mol Sci. 2014 Sep 30;15(10):17644-66
pubmed: 25272224
J Cell Mol Med. 2016 Aug;20(8):1467-80
pubmed: 27019188
Int J Mol Sci. 2014 Jun 12;15(6):10567-77
pubmed: 24927146
J Hepatol. 2018 Feb;68(2):268-279
pubmed: 29122391
PLoS One. 2016 Apr 14;11(4):e0153497
pubmed: 27077736
Int J Endocrinol. 2013;2013:450639
pubmed: 23653642
PLoS One. 2014 Aug 20;9(8):e105192
pubmed: 25141008
Int J Mol Sci. 2018 Mar 19;19(3):
pubmed: 29562725
Clin Chim Acta. 2013 Sep 23;424:99-103
pubmed: 23727030
Clin Endocrinol (Oxf). 2014 Aug;81(2):276-81
pubmed: 24533739
Cell Physiol Biochem. 2016;39(6):2239-2248
pubmed: 27832630
PLoS One. 2010 Oct 29;5(10):e13735
pubmed: 21060830
Sci Rep. 2017 Nov 3;7(1):14493
pubmed: 29101357
Arch Gerontol Geriatr. 2019 May - Jun;82:155-160
pubmed: 30802839
Clin Res Hepatol Gastroenterol. 2017 Sep;41(4):370-377
pubmed: 27956256
Hepatology. 2008 Dec;48(6):1810-20
pubmed: 19030170
Thyroid. 2016 Oct;26(10):1431-1440
pubmed: 27610819
DNA Cell Biol. 2015 Jul;34(7):470-80
pubmed: 25974152
Biochem Biophys Res Commun. 2015 Jul 17-24;463(1-2):60-3
pubmed: 25986735
Ann Clin Biochem. 2018 Jul;55(4):437-445
pubmed: 28920467
J Hepatol. 2018 Dec;69(6):1335-1348
pubmed: 30142428
J Mol Biomark Diagn. 2015 Nov;6(6):
pubmed: 27308097
J Epidemiol. 2020 Apr 5;30(4):177-182
pubmed: 30905898
Mol Biosyst. 2016 Dec 20;13(1):106-121
pubmed: 27869909
Biomed Res Int. 2013;2013:761617
pubmed: 24455723
Mol Cell Endocrinol. 2015 Dec 15;418 Pt 1:55-65
pubmed: 25724480
Life Sci. 2016 Mar 15;149:146-52
pubmed: 26869391
Microrna. 2018;7(2):148-154
pubmed: 29607782
Anal Chem. 2019 May 21;91(10):6746-6753
pubmed: 31002238
J Biomed Sci. 2013 Oct 04;20:72
pubmed: 24093444
Life Sci. 2018 Sep 1;208:201-207
pubmed: 30030064
J Gastroenterol Hepatol. 2013 Dec;28 Suppl 4:64-70
pubmed: 24251707
Biochem Biophys Res Commun. 2015 Dec 4-11;468(1-2):185-9
pubmed: 26519879
Metab Syndr Relat Disord. 2018 Mar;16(2):82-89
pubmed: 29360415
Hepatology. 2006 Jun;43(6):1317-25
pubmed: 16729309
Hepatology. 2011 Sep 2;54(3):1082-1090
pubmed: 21618575
Mol Med Rep. 2018 Sep;18(3):2669-2680
pubmed: 30015905

Auteurs

Yoshitaka Ando (Y)

Department of Biomedical and Analytical Sciences, Fujita Health University School of Medical Sciences, 1-98, Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan.

Mirai Yamazaki (M)

Department of Medical Technology, Kagawa Prefectural University of Health Sciences, 281-1, Murechohara, Takamatsu, Kagawa, 761-0123, Japan.

Hiroya Yamada (H)

Department of Hygiene, Fujita Health University School of Medicine, 1-98, Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan. hyamada@fujita-hu.ac.jp.

Eiji Munetsuna (E)

Department of Biochemistry, Fujita Health University School of Medicine, 1-98, Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan.

Ryosuke Fujii (R)

Department of Preventive Medical Sciences, Fujita Health University School of Medical Sciences, 1-98, Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan.

Genki Mizuno (G)

Department of Joint Research Laboratory of Clinical Medicine, Fujita Health University Hospital, 1-98, Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan.

Naohiro Ichino (N)

Department of Clinical Physiology and Functional Imaging, Fujita Health University School of Medical Sciences, 1-98, Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan.

Keisuke Osakabe (K)

Department of Clinical Physiology and Functional Imaging, Fujita Health University School of Medical Sciences, 1-98, Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan.

Keiko Sugimoto (K)

Department of Clinical Physiology and Functional Imaging, Fujita Health University School of Medical Sciences, 1-98, Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan.

Hiroaki Ishikawa (H)

Department of Biomedical and Analytical Sciences, Fujita Health University School of Medical Sciences, 1-98, Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan.

Koji Ohashi (K)

Department of Biomedical and Analytical Sciences, Fujita Health University School of Medical Sciences, 1-98, Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan.

Ryoji Teradaira (R)

Department of Biomedical and Analytical Sciences, Fujita Health University School of Medical Sciences, 1-98, Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan.

Yoshiji Ohta (Y)

Department of Chemistry, Fujita Health University School of Medicine, 1-98, Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan.

Nobuyuki Hamajima (N)

Department of Healthcare Administration, Nagoya University Graduate School of Medicine, 65, Tsurumai-cho, Showa-ku, Nagoya, Aichi, 466-8550, Japan.

Shuji Hashimoto (S)

Department of Hygiene, Fujita Health University School of Medicine, 1-98, Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan.

Koji Suzuki (K)

Department of Preventive Medical Sciences, Fujita Health University School of Medical Sciences, 1-98, Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan. ksuzuki@fujita-hu.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH